The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Nov 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed indolent non-Hodgkin lymphoma. We assessed the efficacy and safety of lenalidomide plus rituximab in patients with untreated, advanced stage indolent non-Hodgkin lymphoma. ⋯ Celgene Corporation and Richard Spencer Lewis Memorial Foundation and Cancer Center Support Grant.